Fig. 9: TNC downregulation enhances the antitumour activity of PD1 blockade in vivo. | Nature Communications

Fig. 9: TNC downregulation enhances the antitumour activity of PD1 blockade in vivo.

From: Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation

Fig. 9

a 4T1-Atg5KO#1 cells were stably transfected with Tet-on inducible TNC shRNA. Then the cells were treated with DOX for 2 days. b–d Tumour growth of 4T1-Atg5KO#1 cells stably expressing Tet-on inducible TNC shRNA in BALB/c mice following treatment with DOX and PD1 antibody. The treatment protocol was summarized by the arrows (b). Tumour volumes (c) and tumour weights from experiment on autopsy on day 19 (d) were calculated. e Representative images of IHC staining of CD4, CD8 and granzyme B (GB) expression in xenograft tumour sections were shown for mice with treatment in (c) (upper). HPF, ×400 magnification. Scar bar, 50 µm. Quantitative IHC analysis of CD4, CD8 and granzyme B expression (bottom). f Representative images of TUNEL staining (green) and DAPI-stained nuclei (blue) in xenograft tumour sections were shown for mice with treatment in (c) (left). Scar bar, 50 µm. Quantification of positive TUNEL cells (right). Error bars represent mean ± SEM, n = 6 mice per group. The P value in c–f was determined by one-way analysis of ANOVA with Tukey’s multiple comparisons test, no adjustments were made for multiple comparisons. NS no significance. The data are representative of two independent experiments.

Back to article page